Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1
Curated date: 2022/08/29
Curator: Sharmilac
Revision editor(s): Sharmilac, Fatima, WikiWorks, Peace Sandy
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to immunochemotherapy Response to immunochemotherapy,response to immunochemotherapy
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- non-responders (patients treated with conventional dose)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- responders (patients treated with metronomic dose of capecitabine)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with HER2-negative metastatic breast cancer who receive metronomic capecitabine as maintenance treatment.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 16
- Group 1 sample size Number of subjects in the case (exposed) group
- 15
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Signature 1
Source: Table 2, Figure 2B, text
Description: Comparison of the distribution of gut microbiota between the metronomic group and the routine group at different levels. (B) Distribution of the gut microbiota composition in the metronomic group and the routine group at the genus level.
Abundance in Group 1: increased abundance in responders (patients treated with metronomic dose of capecitabine)
| NCBI | Quality Control | Links |
|---|---|---|
| Megamonas | ||
| Veillonellaceae | ||
| Veillonella | ||
| Veillonella sp. | ||
| Veillonellales | ||
| Megamonas sp. | ||
| unclassified Megamonas | ||
| unclassified Veillonella | ||
| unclassified Veillonellaceae |
Signature 2
Source: Table 2, Figure 2B, text
Description: Comparison of the distribution of gut microbiota between the metronomic group and the routine group at different levels.
Abundance in Group 1: decreased abundance in responders (patients treated with metronomic dose of capecitabine)
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia | ||
| Cyanobacteriota | ||
| Streptophyta | ||
| Blautia sp. |
